Trial
NCT02972034
Study of MK-8353 in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Malignancies (MK-8353-013)
Phase ITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Merck Sharp & Dohme LLC
Collaborators
—
Condition
Neoplasms
Intervention
MK-8353
Why stopped
business reasons.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2024-11-21